Townsend Richard Nolan's Form 4/A amendment
AmendedLexeo Therapeutics, Inc.LXEO · filed Sep 10, 2025
- Accession no.
- 0001415889-25-024104
- Filed
- Sep 10, 2025
- Trade date
- Aug 18, 2025
- Filing delay
- 23 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Aug 20, 2025
This filing lists 1 non-derivative transaction. Open-market sales total $5.21K. It was filed 23 days after the trade.
This amendment replaces 0001415889-25-022473 (filed Aug 20, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Townsend Richard NolanCIK 0001995218 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Common Stock | SSaleDisposed | −1,115 | $4.67 | −$5,207.05 | 220,058 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
- F2
On August 20, 2025, the reporting person filed a Form 4 which inadvertently reported the disposition of 2,735 securities. In fact, as reported in this amendment, the reporting person disposed of 1,115 shares of Common Stock on August 18, 2025.
- F3
Includes 131,092 Restricted Stock Units.